Stephen Michael Kelsey - Oct 13, 2025 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President, Research and Development
Signature
/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
Stock symbol
RVMD
Transactions as of
Oct 13, 2025
Transactions value $
-$1,095,290
Form type
4
Date filed
10/15/2025, 05:09 PM
Previous filing
Sep 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kelsey Stephen Michael President, Research and Development C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY /s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey 2025-10-15 0001462808

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $118K +25K +8.8% $4.73 309K Oct 13, 2025 Direct F1, F2
transaction RVMD Common Stock Sale -$1.21M -25K -8.09% $48.54 284K Oct 13, 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -25K -83.18% $0.00 5.06K Oct 13, 2025 Common Stock 25K $4.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.
F2 Includes 84,000 restricted stock units.
F3 The transaction was executed in multiple trades in prices ranging from $48.03 to $48.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President, Research and Development